Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0140-6736(92)90441-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnosis of hepatitis C virus in Brazilian blood donors using a reverse transcriptase nested polymerase chain reaction: comparison with enzyme immunoassay and recombinant protein immunoblot assay.
Rev Inst Med Trop Sao Paulo
November 2000
Centro de Hematologia e Hemoterapia, UNICAMP, Cidade Universitária, Campinas, São Paulo, Brasil.
Screening blood donations for anti-HCV antibodies and alanine aminotransferase (ALT) serum levels generally prevents the transmission of hepatitis C virus (HCV) by transfusion. The aim of the present study was to evaluate the efficiency of the enzyme immunoassay (EIA) screening policy in identifying potentially infectious blood donors capable to transmit hepatitis C through blood transfusion. We have used a reverse transcriptase (RT)-nested polymerase chain reaction (PCR) to investigate the presence of HCV-RNA in blood donors.
View Article and Find Full Text PDFPerformance of hepatitis C virus (HCV) antibody test systems in relation to HCV-RNA detection in the diagnosis of HCV infection.
Dan Med Bull
February 1998
Department of Clinical Chemistry, Aalborg Hospital.
Background: Hepatitis C virus antibody (anti-HCV) test systems for screening and confirmation of blood donations have proved their value. The systems were later adopted for diagnosing patients suspected of hepatitis C.
Objectives: 1) to study the clinical value of the recombinant immunoblot assay (RIBA) in routine diagnostics of patients suspected of HCV infection using HCV-PCR as the most definitive test and 2) to compare the performance of RIBA-2 with RIBA-3.
Indeterminate results of the second-generation hepatitis C virus (HCV) recombinant immunoblot assay: significance of high-level c22-3 reactivity and influence of HCV genotypes.
J Clin Microbiol
January 1997
Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
A second-generation recombinant immunoblot assay (RIBA 2.0) is used in the United States to confirm infection with hepatitis C virus (HCV) in samples that are anti-HCV (enzyme immunoassay) positive. In some cases, indeterminate results of RIBA 2.
View Article and Find Full Text PDFThird-generation recombinant immunoblot assay: comparison of reactivities according to hepatitis C virus genotype.
Transfusion
June 1996
Scottish National Blood Transfusion Service Microbiology Reference Unit, Regional Virus Laboratory, Ruchill Hospital, Glasgow, United Kingdom.
Background: Recombinant immunoblot assay (RIBA) is widely used as a supplemental test in hepatitis C virus (HCV) confirmatory algorithms. As this assay is based on HCV type 1, its performance was examined with the common European HCV genotypes (1, 2, and 3).
Study Design And Methods: A study was performed to retest in third-generation RIBA (RIBA-3) all 146 second-generation RIBA (RIBA-2)-positive polymerase chain reaction-positive samples detected by second-generation enzyme-linked immunosorbent assays and having known HCV genotypes (74 HCV type 1, 21 type 2, 51 type 3).
Reliability of the third-generation recombinant immunoblot assay for hepatitis C virus.
Transfusion
September 1995
Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, Amsterdam.
Background: In a confirmatory laboratory, the second-generation recombinant immunoblot assay (RIBA-2) was replaced by the third-generation RIBA (RIBA-3) in March 1993. The aim of this validation study was to compare the sensitivity and specificity of RIBA-2 and RIBA-3 in a routine setting, by using a validated hepatitis C virus (HCV) RNA polymerase chain reaction to establish plasma viremia.
Study Design And Methods: RIBA-2 testing was performed (March 1991-March 1993) in 593 HCV RNA-positive and 1498 HCV RNA-negative subjects.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!